Business
Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation
Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / November 19, 2020 / Halberd Corp. (OTC PINK:HALB) reported the filing of a provisional patent application on a variation of Halberd's patented extracorporeal method to treat/eradicate Covid-19 from a patient's blood. By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects than with more conventional treatment regimens.Halberd's provisional patent application, "Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus," discloses a unique application of extracorporeal exposure of virus-infected blood to a specifically created antibody which has been demonstrated to bind with the virus, but without deleterious side effects. This conjugate antibody/antigen pair is designed to react to an externally applied specific radio frequency which destroys the virus-antibody pair in real-time.Dr. Mitchell S. Felder, inventor of this technology and consultant to Halberd Corporation's Scientific Advisory Board, stated, "A pathogen binding antibody binds to the target antigen and includes a moiety that reacts to a specific radio frequency. The result is the disease-causing pathogen is destroyed without further harm to the patient. This process could be similarly employed on any number of blood-borne diseases."William A. Hartman, Chairman, President & CEO, added, "Of all the methods we have investigated, this seems to be the easiest and most effective in eliminating Covid-19 antigens. This would be intended to be administered in a hospital setting to those patients most adversely affected by Covid-19. The development of this technology will not interfere with, or otherwise delay, pursuit of our twin number one priorities -- nasal spray preventative and fluorescent antibody rapid diagnostic test."The details of the Halberd-ASU research contract can be viewed here.If you would like to be added to our email subscriber list, click here and submit the form.For more information please contact:William A. [email protected];[email protected]:@HalberdCAbout Halberd Corporation.Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in f...